Market Place
Sourcing Support
Signatera MRD Data at ASCO GU Support Use Across GU Cancers
27 Feb 2026 //
BUSINESSWIRE
Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment
24 Feb 2026 //
BUSINESSWIRE
Natera Submits Signatera CDx PMA to FDA
02 Feb 2026 //
BUSINESSWIRE
Natera Completes Enrollment In Randomized ACES-EMB Trial
28 Jan 2026 //
BUSINESSWIRE
Natera, NVIDIA Scale AI for Precision Medicine
12 Jan 2026 //
BUSINESSWIRE
Natera Unveils ALTAIR Trial Updates At ASCO GI
05 Jan 2026 //
BUSINESSWIRE
Natera Unveils Signatera in CALGB/SWOG CRC Study
18 Dec 2025 //
BUSINESSWIRE
I-SPY 2: Signatera Predicts Early Breast Cancer Recurrence
16 Dec 2025 //
BUSINESSWIRE
Natera and MEDSIR to Collaborate on the MiRaDoR Trial
12 Dec 2025 //
BUSINESSWIRE
Natera Presents Lymphoma Discoveries At ASH Conference
09 Dec 2025 //
BUSINESSWIRE
Signatera Data In Lymphoma And Multiple Myeloma Revealed
03 Dec 2025 //
BUSINESSWIRE
Natera Unveils Signatera Data from 50K+ Patients at ASCO
02 Dec 2025 //
BUSINESSWIRE
IMvigor011 Shows 41% OS Gain In Bladder Cancer Patients
20 Oct 2025 //
BUSINESSWIRE
Natera Named To Fast Company`s Next Big Things In Tech List
16 Oct 2025 //
BUSINESS WIRE
Natera To Showcase 14 Studies At ESMO, Featuring IMvigor011
14 Oct 2025 //
BUSINESSWIRE
Natera Hosts Investor Call On October 23, 2025 For ESMO Findings
13 Oct 2025 //
BUSINESSWIRE
Enrollment Tops 1600 in Natera’s EXPAND Trial of Single Gene NIPT
01 Oct 2025 //
BUSINESSWIRE
Natera Publishes Signatera™ Validation Study In Testicular Cancer
30 Sep 2025 //
BUSINESSWIRE
Signatera Picked for NRG Ph 3 ARCHER Trial in Bladder Cancer
28 Aug 2025 //
BUSINESSWIRE
IMvigor011 Shows Positive Results, Signatera Predicts Benefit
18 Aug 2025 //
BUSINESSWIRE
Natera Highlights Latitude™ MRD in Colorectal Cancer at ESMO
07 Jul 2025 //
BUSINESSWIRE
Natera to Present Signatera Data at ESMO GI Conference
01 Jul 2025 //
BUSINESSWIRE
Natera Announces Medicare Coverage for Signatera Genome
04 Jun 2025 //
BUSINESSWIRE
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
02 Jun 2025 //
BUSINESSWIRE
Natera to Present 25+ Signatera Studies at 2025 ASCO Meeting
22 May 2025 //
BUSINESSWIRE
Largest Sarcoma Study Shows Signatera`s Excellent Performance
05 May 2025 //
BUSINESSWIRE
Natera to Report its First Quarter Results on May 8, 2025
01 May 2025 //
BUSINESSWIRE
Natera Launches Signatera Genome MRD Test
24 Apr 2025 //
BUSINESSWIRE
Natera Enrolls First Patients In HEROES Trial For HER2+ Breast Cancer
10 Mar 2025 //
BUSINESSWIRE
Natera Completes Signatera™ Analysis from CALGB/SWOG 80702 Trial
12 Nov 2024 //
BUSINESSWIRE
Natera To Present New Signatera CRC Data At ESMO
08 Sep 2024 //
BUSINESSWIRE
Natera Announces Positive Analysis from the Randomized Ph III IMvigor011 Trial
05 Apr 2024 //
BUSINESSWIRE
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment
06 Dec 2023 //
BUSINESSWIRE
Updated Data from CIRCULATE-Japan Presented at ESMO 2023
22 Oct 2023 //
BUSINESSWIRE
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility
08 May 2023 //
BUSINESSWIRE
Foundation Medicine and Natera Announce the Launch of FoundationOneTracker
08 Jan 2023 //
BUSINESSWIRE
